Palliative care for advanced Parkinson disease: An interdisciplinary clinic and new scale, the ESAS-PD

Long, J. J.; Mancini, Deborah; Moro, Elena; Fox, Susan H.; Lang, Anthony E.; Marras, Connie; Chen, Robert; Strafella, Antonio P.; Arshinoff, Rena; Ghoche, Roger; Hui, Jeanette

doi:10.1016/j.parkreldis.2012.06.013

Cited by 114 publications

(107 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…10 However, it has since even been used in various other cancer and non-cancer populations. 17, 18 In our study, we tested the K-ESAS in a population of Korean patients seen at oncology clinics. Chang et al 19 also used oncology outpatients to validate the English version of the ESAS, and, as in our study, their results indicated good internal consistency and reliability.…”

Section: Discussionmentioning

confidence: 99%

Validation of the Edmonton Symptom Assessment System in Korean Patients With Cancer

Kwon

Nam

Koh

et al. 2013

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

Context The Edmonton Symptom Assessment System (ESAS) is a brief, widely adopted multidimensional questionnaire to evaluate patient-reported symptoms. Objectives To develop a Korean version of the ESAS (K-ESAS) and to perform a psychometric analysis in Korean patients with advanced cancer. Methods We tested the K-ESAS in two pilot studies with 15 patients each. We assessed internal consistency, test-retest reliability, and concurrent validity in 163 Korean patients, who completed the K-ESAS along with the Korean versions of the M. D. Anderson Symptom Inventory (K-MDASI) and the Hospital Anxiety and Depression Scale (K-HADS) twice. Thirty-eight patients completed the questionnaires again seven days later to assess responsiveness. Results K-ESAS scores had good internal consistency, with a Cronbach’s alpha coefficient of 0.88, indicating that no questions had undue influence on the score. Pearson correlation coefficients for K-ESAS symptom scores between baseline and after 2–4 hours ranged from 0.72 (95% confidence interval [CI] 0.64, 0.79) to 0.87 (95% CI 0.82, 0.90), indicating strong test-retest reliability. For concurrent validity, Pearson correlation coefficients between K-ESAS symptom scores and corresponding K-MDASI symptom scores ranged from 0.70 (95% CI 0.62, 0.77) to 0.83 (95% CI 0.77, 0.87), indicating good concurrent validity. For the K-HADS, concurrent validity was good for anxiety (r = 0.73, 95% CI 0.65, 0.79) but moderate for depression (r = 0.4, 95% CI 0.26, 0.52). For responsiveness, changes in K-ESAS scores after seven days were moderately correlated with changes in K-MDASI scores but weakly correlated with changes in K-HADS scores. Conclusion The K-ESAS is a valid and reliable tool for measuring multidimensional symptoms in Korean cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Validation of the Edmonton Symptom Assessment System in Korean Patients With Cancer

Kwon

Nam

Koh

et al. 2013

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

show abstract

“…Individuals with PD who are hospitalized are often subjected to delayed treatment, contraindicated medications, prolonged immobility, lengthy stays, and high mortality. 5,6 Second, although some comprehensive and distributed PD care models 3,7 are quite effective, few patients receive such care, and many PD-related hospitalizations are likely preventable. 8 Third and fourth, providing patient-centered care that is timely has been rarely studied.…”

Section: The Shortcomings Of Current Carementioning

confidence: 99%

Moving Parkinson care to the home

Dorsey

Vlaanderen²,

Engelen

et al. 2016

Mov Disord.

View full text Add to dashboard Cite

In many ways, the care of individuals with Parkinson disease does not meet their needs. Despite the documented benefits of receiving care from clinicians with Parkinson disease expertise, many patients (if not most) do not. Moreover, current care models frequently require older individuals with impaired mobility, cognition, and driving ability to be driven by overburdened caregivers to large, complex urban medical centers. Moving care to the patient's home would make Parkinson disease care more patient‐centered. Demographic factors, including aging populations, and social factors, such as the splintering of the extended family, will increase the need for home‐based care. Technological advances, especially the ability to assess and deliver care remotely, will enable the transition of care back to the home. However, despite its promise, this next generation of home‐based care will have to overcome barriers, including outdated insurance models and a technological divide. Once these barriers are addressed, home‐based care will increase access to high quality care for the growing number of individuals with Parkinson disease. © 2016 International Parkinson and Movement Disorder Society

show abstract

“…Nevertheless, an international survey of 11 countries found that a substantial proportion (up to 75% in some countries) of PD deaths occurred in the hospital setting [94]. A key barrier to the development of palliative care pathways is the lack of evidence-based knowledge on how to build a service that integrates neurological and palliative care [95,96]. Uncertainty about the timing of palliative care means that often it is not considered until a patient reaches crisis point, despite the recognized need for early planning due to increased prevalence of dementia [97].…”

Section: Nursing Home and End Of Life/palliativementioning

confidence: 99%

Unmet needs in Parkinson's disease: New horizons in a changing landscape

Bhidayasiri

Laar

2016

Parkinsonism & Related Disorders

View full text Add to dashboard Cite

a b s t r a c tThe success of levodopa and other classes of drugs have meant that most people with Parkinson's disease enjoy a good quality of life for many years. However, despite the availability of several drugs and formulations that can be used as monotherapy and in combination, there are a number of disease features that the current therapies are unable to address. The disease continues to progress despite treatment, patients suffer from a myriad of motor and non-motor symptoms, and a neuroprotective therapy is urgently required. To move forward with medical and surgical management, it is important to consider new insights that recent research offers and in this review we examine how a better understanding of the disease pathology and progression might improve and enrich our daily clinical practice. It is also timely to consider the service provision changes that will increasingly be needed to effectively manage the needs of the aging population.

show abstract

Palliative care for advanced Parkinson disease: An interdisciplinary clinic and new scale, the ESAS-PD

Cited by 114 publications

References 14 publications

Validation of the Edmonton Symptom Assessment System in Korean Patients With Cancer

Validation of the Edmonton Symptom Assessment System in Korean Patients With Cancer

Moving Parkinson care to the home

Unmet needs in Parkinson's disease: New horizons in a changing landscape

Contact Info

Product

Resources

About